Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined with Cryoablation for Oligo-progressive NSCLC
NCT06127303Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Apr 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06127303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127303.